GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xtant Medical Holdings Inc (AMEX:XTNT) » Definitions » EBIT

XTNT (Xtant Medical Holdings) EBIT : $-13.0 Mil (TTM As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Xtant Medical Holdings EBIT?

Xtant Medical Holdings's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $-3.8 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $-13.0 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Xtant Medical Holdings's annualized ROC % for the quarter that ended in Sep. 2024 was -20.43%. Xtant Medical Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -25.75%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Xtant Medical Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -15.51%.


Xtant Medical Holdings EBIT Historical Data

The historical data trend for Xtant Medical Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xtant Medical Holdings EBIT Chart

Xtant Medical Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.35 -0.75 -3.85 -6.72 1.90

Xtant Medical Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.69 -2.91 -3.50 -2.83 -3.76

Competitive Comparison of Xtant Medical Holdings's EBIT

For the Medical Devices subindustry, Xtant Medical Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xtant Medical Holdings's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xtant Medical Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Xtant Medical Holdings's EV-to-EBIT falls into.



Xtant Medical Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xtant Medical Holdings  (AMEX:XTNT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Xtant Medical Holdings's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-15.108 * ( 1 - -1.25% )/( (74.648 + 75.117)/ 2 )
=-15.29685/74.8825
=-20.43 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Xtant Medical Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-15.052/( ( (9.954 + max(48.042, 0)) + (11.279 + max(47.645, 0)) )/ 2 )
=-15.052/( ( 57.996 + 58.924 )/ 2 )
=-15.052/58.46
=-25.75 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(21.187 + 40.507 + 1.899) - (15.551 + 0 + 0)
=48.042

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(20.545 + 41.886 + 2.383) - (17.169 + 0 + 0)
=47.645

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Xtant Medical Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-13.001/83.818
=-15.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xtant Medical Holdings EBIT Related Terms

Thank you for viewing the detailed overview of Xtant Medical Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Xtant Medical Holdings Business Description

Traded in Other Exchanges
Address
664 Cruiser Lane, Belgrade, MT, USA, 59714
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.
Executives
Kevin D Brandt officer: VP & Chief Commercial Officer 11621 RESEARCH CIRCLE, ALACHUA FL 32615
Lori D Mitchell-keller director 664 CRUISER LANE, BELGRADE MT 59714
Jonn R. Beeson director 664 CRUISER LANE, BELGRADE MT 59714
Scott C Neils officer: Interim CFO 664 CRUISER LANE, BELGRADE MT 59714
Mark A. Schallenberger officer: Chief Operations Officer 664 CRUISER LANE, BELGRADE MT 59714
Sean E Browne officer: President and CEO 664 CRUISER LANE, BELGRADE MT 59714
Stavros G. Vizirgianakis director 1/16-18 TENNYSON ST., WILLIAMSTOWN NORTH, VICTORIA CA 3016
Orbimed Rof Ii Llc director, 10 percent owner 601 LEXINGTON AVE., 54TH FLOOR, NEW YORK NY 10022
Greg Jensen officer: VP, Finance and Interim CFO 664 CRUISER LANE, BELGRADE MT 59714
Ronald G. Berlin officer: VP & Chief Operations Officer 664 CRUISER LANE, BELGRADE MT 59714
Kathie J. Lenzen officer: SVP Fiance & Admin. & CFO 664 CRUISER LANE, BELGRADE MT 59714
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Matthew Rizzo director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Michael Eggenberg director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Robert Mcnamara director C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750